Haematology of down syndrome

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 92, Issue 6, 2007, Pages

  Webb, David ^b   Roberts, Irene ^c   Vyas, Paresh ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD CELL COUNT; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CHILDHOOD DISEASE; CHILDHOOD LEUKEMIA; DISEASE ASSOCIATION; DOWN SYNDROME; HEMATOLOGIC DISEASE; HUMAN; MYELOPOIESIS; NEWBORN DISEASE; PRIORITY JOURNAL; REGISTER; REVIEW;

CHILD, PRESCHOOL; DOWN SYNDROME; HEMATOLOGIC DISEASES; HUMANS; INFANT; INFANT, NEWBORN;

EID: 35948953281     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2006.104638     Document Type: Review

References (37)

1. Miller M, Cosgriff JM. Hematological abnormalities in newborn infants with Down syndrome. Am J Med Genet 1983;16:173-7.
2. David O, Fiorucci G, Tosi M, et al. Hematological studies in children with Down syndrome. Pediatr Hematol Oncol 1996;13:271-5.
3. de Hingh YC, van der Vossen PW, Gemen EF, et al. Intrinsic abnormalities of lymphocyte counts in children with down syndrome. J Pediatr 2005;147:744-7.
4. Walts TL, Murray NA, Roberts IA. Thrombopoietin has a primary role in the regulation of platelet production in preterm babies. Pediatr Res 1999;46:28-32.
5. Richards M, Welch J, Watmore A, et al. Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome. Arch Dis Child Fetal Neonatal Ed 1998;79:F215-7.
6. Choong K, Freedman MH, Chitayat D, et al. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol 1999;21:523-7.
7. Zipursky A. Transient leukaemia - a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 2003;120:930-8.
8. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006;107:4606-13.
9. Wechsler J, Greene M, McDevilt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002;32:148-52.
10. Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003;101:4301-4.
11. Groet J, McElwaine S, Spinelli M, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 2003;361:1617-20.
12. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003;102:981-6.
13. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004;103:2480-9.
14. Robertson M, De Jong G, Mansvelt E. Prenatal diagnosis of congenital leukemia in a fetus at 25 weeks' gestation with Down syndrome: case report and review of the literature. Ultrasound Obstet Gynecol 2003;21:486-9.
15. Kivivuori SM, Rajantie J, Siimes MA. Peripheral blood cell counts in infants with Down's syndrome. Clin Genet 1996;49:15-9.
16. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliterative diseases. Leukemia 2003;17:277-82.
17. Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005;19:1355-60.
18. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol 1992;9:139-49.
19. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165- 9.
20. Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia 1996;10:1677-86.
21. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 1998;91:608-15.
22. Zeller B, Gustafsson G, Forestier E, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005;128:797-804.
23. Craze JL, Harrison G, Wheatley K, et al. Improved outcome of acute myeloid leukaemia in Down's syndrome. Arch Dis Child 1999;81:32-7.
24. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 2005;44:33-9.
25. Rao A, Hills RK, Stiller C, et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006;132:576-83.
26. Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 2003;102:2960-8.
27. Vyos P, Roberts I. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis. Early Hum Dev 2006;82:767-73.
28. Carpenter E, Valverde-Garduno V, Sternberg A, et al. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol 2005;128:548-51.
29. Kuhl C, Atzberger A, Iborra F, B. N, C. P, P. V. GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1. Mol Cell Biol 2005;25:8592-606.
30. Li Z, Godinho FJ, Klusmann JH, et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005;37:613-9.
31. Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interadion surface of GATA-1 in megakaryocyte gene expression and development. Blood 2005;106:1223-31.
32. Stachura DI, Chou ST, Weiss MJ. Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. Blood 2006;107:87-97.
33. Webb DK. Optimizing therapy for myeloid disorders of Down syndrome. Br J Haematol 2005;131:3-7.
34. Ragab AH, Abdel-Mageed A, Shuster JJ, et al. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome. A Pediatric Oncology Group study. Cancer 1991;67:1057-63.
35. Dordelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 1998;12:645-51.
36. Chessells JM, Harrison G, Richards SM, et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 2001;85:321-5.
37. Whitlock JA, Sather HN, Gaynon P, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2005;106:4043-9.